TAGAT; Jayaram R.
Patent Applications and Registrations
Patent applications and USPTO patent grants for TAGAT; Jayaram R..The latest application filed is for "imidazo[1,2-c]quinazolin-5-amine compounds with a2a antagonist properties".
- TAGAT; Jayaram R. - Westfield NJ
| Patent | Date |
|---|---|
| Imidazo[1,2-c]quinazolin-5-amine Compounds With A2a Antagonist Properties App 20210053973 - ALI; Amjad ; et al. | 2021-02-25 |
| Aminoquinazoline compounds as A.sub.2A antagonist Grant 10,138,212 - Ali , et al. Nov | 2018-11-27 |
| Aminoquinazoline Compounds As A2a Antagonist App 20180037554 - Ali; Amjad ; et al. | 2018-02-08 |
| Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A.sub.2A antagonist properties Grant 9,676,780 - Ali , et al. June 13, 2 | 2017-06-13 |
| Piperazine-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine Compounds With A2a Antagonist Properties App 20160194330 - Ali; Amjad ; et al. | 2016-07-07 |
| Heterocyclic compounds as ERK inhibitors Grant 8,999,957 - Deng , et al. April 7, 2 | 2015-04-07 |
| Novel Heterocyclic Compounds As Erk Inhbitors App 20130096084 - Deng; Yongqi ; et al. | 2013-04-18 |
| Piperazine derivatives useful as CCR5 antagonists Grant 8,114,879 - Baroudy , et al. February 14, 2 | 2012-02-14 |
| Piperidine Derivatives Useful As Ccr5 Antagonists App 20080188485 - Baroudy; Bahige M. ; et al. | 2008-08-07 |
| Piperazine derivatives useful as CCR5 antagonists Grant 7,384,944 - Baroudy , et al. June 10, 2 | 2008-06-10 |
| Compositions comprising a combination of CCR5 and CXCR4 antagonists App 20070123538 - Dunkle; Lisa ; et al. | 2007-05-31 |
| Compounds for inhibiting KSP Kinesin activity App 20060281778 - Tagat; Jayaram R. ; et al. | 2006-12-14 |
| Compounds for inhibiting KSP kinesin activity App 20060247320 - Tagat; Jayaram R. ; et al. | 2006-11-02 |
| Piperazine derivatives useful as CCR5 antagonists App 20040067961 - Baroudy, Bahige M. ; et al. | 2004-04-08 |
| Piperazine derivatives useful as CCR5 antagonists Grant 6,689,765 - Baroudy , et al. February 10, 2 | 2004-02-10 |
| Piperidine derivatives useful as CCR5 antagonists Grant 6,602,885 - Baroudy , et al. August 5, 2 | 2003-08-05 |
| Piperazine derivatives useful as CCR5 antagonists App 20030069252 - Baroudy, Bahige M. ; et al. | 2003-04-10 |
| Piperidine derivatives useful as CCR5 antagonists App 20030004185 - Baroudy, Bahige M. ; et al. | 2003-01-02 |
| Muscarinic antagonists App 20020103205 - Lowe, Derek ; et al. | 2002-08-01 |
| Piperazine derivatives useful as CCR5 antagonists Grant 6,391,865 - Baroudy , et al. May 21, 2 | 2002-05-21 |
| Piperidine derivatives useful as CCR5 antagonists Grant 6,387,930 - Baroudy , et al. May 14, 2 | 2002-05-14 |
| Muscarinic antagonists Grant 6,066,636 - Kozlowski , et al. May 23, 2 | 2000-05-23 |
| Muscarinic antagonists Grant 6,043,255 - Lowe , et al. March 28, 2 | 2000-03-28 |
| Muscarinic antagonists Grant 6,037,352 - Lowe , et al. March 14, 2 | 2000-03-14 |
| Muscarinic antagonists Grant 5,889,006 - Lowe , et al. March 30, 1 | 1999-03-30 |
| Muscarinic antagonists Grant 5,883,096 - Lowe , et al. March 16, 1 | 1999-03-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 